Molecular pathology of Lewy body diseases
- PMID: 19399218
- PMCID: PMC2671999
- DOI: 10.3390/ijms10030724
Molecular pathology of Lewy body diseases
Abstract
Lewy body diseases are characterized by the presence of Lewy bodies, alpha-synuclein(AS)-positive inclusions in the brain. Since their main component is conformationally modified AS, aggregation of the latter is thought to be a key pathogenic event in these diseases. The analysis of inclusion body constituents gives additional information about pathways also involved in the pathology of synucleinopathies. Widespread mitochondrial dysfunction is very closely related to disease development. The impairment of protein degradation pathways, including both the ubiquitin-proteasome system and the autophagy-lysosome pathway also play an important role during the development of Lewy body diseases. Finally, differential expression changes of isoforms corresponding to genes primarily involved in Lewy body formation point to alternative splicing as another important mechanism in the development of Parkinson's disease, as well as dementia with Lewy bodies. The present paper attempts to give an overview of recent molecular findings related to the pathogenesis of Lewy body diseases.
Keywords: Lewy body diseases; Parkinson disease; alpha-synuclein; alternative splicing; dementia with Lewy bodies; differential isoform expression; mitochondrial dysfunction; molecular chaperones; proteosomal dysfunction.
Similar articles
-
The genetics of dementia with Lewy bodies: what are we missing?Arch Neurol. 2012 Sep;69(9):1113-8. doi: 10.1001/archneurol.2011.3678. Arch Neurol. 2012. PMID: 22635379 Review.
-
α-Synuclein posttranslational modification and alternative splicing as a trigger for neurodegeneration.Mol Neurobiol. 2013 Apr;47(2):509-24. doi: 10.1007/s12035-012-8330-5. Epub 2012 Aug 25. Mol Neurobiol. 2013. PMID: 22923347 Review.
-
Synphilin isoforms and the search for a cellular model of lewy body formation in Parkinson's disease.Cell Cycle. 2006 Sep;5(18):2082-6. doi: 10.4161/cc.5.18.3209. Epub 2006 Sep 15. Cell Cycle. 2006. PMID: 16969096 Review.
-
Ubiquitination of alpha-synuclein in Lewy bodies is a pathological event not associated with impairment of proteasome function.J Biol Chem. 2003 Nov 7;278(45):44405-11. doi: 10.1074/jbc.M308041200. Epub 2003 Aug 15. J Biol Chem. 2003. PMID: 12923179
-
The Role of alpha-synuclein assembly and metabolism in the pathogenesis of Lewy body disease.J Mol Neurosci. 2004;24(3):343-52. doi: 10.1385/JMN:24:3:343. J Mol Neurosci. 2004. PMID: 15655259 Review.
Cited by
-
The Nigral Coup in Parkinson's Disease by α-Synuclein and Its Associated Rebels.Cells. 2021 Mar 9;10(3):598. doi: 10.3390/cells10030598. Cells. 2021. PMID: 33803185 Free PMC article. Review.
-
Neuroinflammation in Parkinson's Disease and Related Disorders: A Lesson from Genetically Manipulated Mouse Models of α-Synucleinopathies.Parkinsons Dis. 2012;2012:271732. doi: 10.1155/2012/271732. Epub 2012 Mar 25. Parkinsons Dis. 2012. PMID: 22550610 Free PMC article.
-
The Neuroprotective Effects of Cannabis-Derived Phytocannabinoids and Resveratrol in Parkinson's Disease: A Systematic Literature Review of Pre-Clinical Studies.Brain Sci. 2021 Nov 28;11(12):1573. doi: 10.3390/brainsci11121573. Brain Sci. 2021. PMID: 34942876 Free PMC article. Review.
-
Molecular Signatures of Neuroinflammation Induced by αSynuclein Aggregates in Microglial Cells.Front Immunol. 2020 Jan 31;11:33. doi: 10.3389/fimmu.2020.00033. eCollection 2020. Front Immunol. 2020. PMID: 32082315 Free PMC article.
-
Plasma and cerebrospinal fluid ABeta42 for the differential diagnosis of Alzheimer's disease dementia in participants diagnosed with any dementia subtype in a specialist care setting.Cochrane Database Syst Rev. 2021 Feb 10;2(2):CD010945. doi: 10.1002/14651858.CD010945.pub2. Cochrane Database Syst Rev. 2021. PMID: 33566374 Free PMC article.
References
-
- Braak H, Del Tredici K, Bratzke H, Hamm-Clement J, Sandmann-Keil D, Rüb U. Staging of the intracerebral inclusion body pathology associated with idiopathic Parkinson’s disease (preclinical and clinical stages) J Neurol. 2002;249(III):1–5. - PubMed
-
- Braak H, Rub U, Gai WP, Del Tredici K. Idiopathic Parkinson’s disease: Possible routes by which vulnerable neuronal types may be subject to neuroinvasion by an unknown pathogen. J. Neural. Transm. 2003;110:517–536. - PubMed
-
- Kruger R, Kuhn W, Muller T, Woitalla D, Graeber M, Kösel S, Przuntek H, Epplen JT, Schöls L, Riess O. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson’s disease. Nat. Genet. 1998;18:106–108. - PubMed
-
- Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A, Pike B, Root H, Rubenstein J, Boyer R, et al. Mutation in the alpha-synuclein gene identified in families with Parkinson’s disease. Science. 1997;276:2045–2047. - PubMed
-
- Zarranz JJ, Alegre J, Gomez-Esteban JC, Lezcano E, Ros R, Ampuero I, Vidal L, Hoenicka J, Rodriguez O, Atarés B, et al. The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Ann. Neurol. 2004;55:164–173. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials